Detalhe da pesquisa
1.
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Wellcome Open Res
; 8: 450, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813551
2.
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Sci Transl Med
; 15(682): eabn5993, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36753561
3.
Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection.
JCI Insight
; 6(17)2021 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264864